Beneficial Impact of CCL2 and CCL12 Neutralization on Experimental Malignant Pleural Effusion

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Marazioti, Antonia ^a   Kairi, Chrysoula A ^b   Spella, Magda ^a   Giannou, Anastasios D ^a   Magkouta, Sophia ^b   Giopanou, Ioanna ^a   Papaleonidopoulos, Vassilios ^a   Kalomenidis, Ioannis ^b   Snyder, Linda A ^c   Kardamakis, Dimitrios ^a   Stathopoulos, Georgios T ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Janssen R and D LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C 1142; C 1450A; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 5; MONOCYTE CHEMOTACTIC PROTEIN 5 ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TARGETING; EXTRAVASATION; HUMAN; HUMAN CELL; INFLAMMATION; LUNG ADENOCARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLEURA EFFUSION; MOUSE; NONHUMAN; PLEURA EFFUSION; SCID MOUSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL2; COLONIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MONOCYTE CHEMOATTRACTANT PROTEINS; PLEURAL EFFUSION, MALIGNANT;

EID: 84881519845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071207     Document Type: Article

References (45)

1. Maskell NA, (2012) Treatment options for malignant pleural effusions: patient preference does matter. JAMA 307: 2432-2433.
2. Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, et al. (2012) Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J, In press.
3. Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, et al. (2008) Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur Respir J 32: 1321-1327.
4. Puri V, Pyrdeck TL, Crabtree TD, Kreisel D, Krupnick AS, et al. (2012) Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg 94: 374-379.
5. Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, et al. (2012) Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 307: 2383-2389.
6. Stathopoulos GT, Kalomenidis I, (2012) Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med 186: 487-492.
7. Froudarakis ME, (2012) Pleural effusion in lung cancer: more questions than answers. Respiration 83: 367-376.
8. Kalomenidis I, (2011) Beyond talc pleurodesis: do we really need new methods? Respirology 16: 1020-1022.
9. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson WE, et al. (2006) Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34: 142-150.
10. Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, et al. (2007) Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 67: 9825-9834.
11. Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, et al. (2010) Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med 182: 1273-1281.
12. Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, et al. (2013) Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene 32: 528-535.
13. Moschos C, Psallidas I, Kollintza A, Karabela S, Papapetropoulos A, et al. (2009) The angiopoietin/Tie2 axis mediates malignant pleural effusion formation. Neoplasia 11: 298-304.
14. Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, et al. (2010) Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study. Mol Cancer 9: 56.
15. Moschos C, Psallidas I, Cottin T, Kollintza A, Papiris S, et al. (2011) A sulindac analogue is effective against malignant pleural effusion in mice. Lung Cancer 73: 171-175.
16. Stathopoulos GT, (2011) Translational advances in pleural malignancies. Respirology 16: 53-63.
17. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, et al. (2008) Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 178: 50-59.
18. Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, et al. (2008) A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 100: 1464-1476.
19. Tsui P, Das A, Whitaker B, Tornetta M, Stowell N, et al. (2007) Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies. Hum Antibodies 16: 117-125.
20. Koller FL, Hwang DG, Dozier EA, Fingleton B, (2010) Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 31: 1010-1017.
21. Cao YA, Bachmann MH, Beilhack A, Yang Y, Tanaka M, et al. (2005) Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation 80: 134-139.
22. Schneider CA, Rasband WS, Eliceiri KW, (2012) NIH Image to ImageJ: 25 years of image analysis. Nature Methods 9: 671-675.
23. Magkouta S, Stathopoulos GT, Psallidas I, Papapetropoulos A, Kolisis FN, et al. (2009) Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma. Nutr Cancer 61: 640-648.
24. Pichelmayer O, Gruenberger B, Zielinski C, Raderer M, (2006) Bevacizumab is active in malignant effusion. Ann Oncol 17: 1853.
25. Zaynagetdinov R, Sherrill TP, Kendall PL, Segal BH, Weller KP, et al. (2013) Identification of Myeloid Cell Subsets in Murine Lungs Using Flow Cytometry. Am J Respir Cell Mol Biol, In press.
26. Light RW, (1997) Diagnostic principles in pleural disease. Eur Respir J 10: 476-481.
27. Good JT Jr, Taryle DA, Sahn SA, (1985) The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 131: 737-741.
28. Sarafi MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD, (1997) Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med 185: 99-109.
29. Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, et al. (2010) CCL2 blockade augments cancer immunotherapy. Cancer Res 70: 109-118.
30. Lee YC, Wilkosz S, (2008) Malignant pleural effusions: fixing the leaky faucet. Am J Respir Crit Care Med 178: 3-5.
31. Hanahan D, Weinberg RA, (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
32. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29: 1093-1102.
33. Muller WA, (2001) New mechanisms and pathways for monocyte recruitment. J Exp Med 194: F47-F51.
34. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, et al. (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
35. Huang B, Lei Z, Zhao J, Gong W, Liu J, et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252: 86-92.
36. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, et al. (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 44: 230-237.
37. Broermann A, Winderlich M, Block H, Frye M, Rossaint J, et al. (2011) Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. J Exp Med 208: 2393-2401.
38. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, et al. (2000) Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 157: 1893-1903.
39. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, et al. (1999) Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5: 3364-3368.
40. Maker AV, Nguyen DM, (2005) Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope. Ann Thorac Surg 80: 1941.
41. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, et al. (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96: 34-40.
42. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
43. Zhang J, Patel L, Pienta KJ, (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21: 41-48.
44. Munson JM, Bellamkonda RV, Swartz MA, (2013) Interstitial Flow in a 3D Microenvironment Increases Glioma Invasion by a CXCR4-Dependent Mechanism. Cancer Res 73: 1536-1546.
45. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, et al. (2012) Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 31: 760-768.